Get the Stockscreener App
12.72
2.32%
-0.2898
Arcus Biosciences Inc stock is traded at $12.72, with a volume of 142.16K.
It is down -2.32% in the last 24 hours and down -16.61% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$13.01
Open:
$13.01
24h Volume:
142.16K
Relative Volume:
0.22
Market Cap:
$1.19B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-4.1166
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-1.49%
1M Performance:
-16.61%
6M Performance:
-9.23%
1Y Performance:
-14.31%
1-Day Range:
$12.58
$13.05
1-Week Range:
$12.53
$13.80
52-Week Range:
$12.53
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
12.73 | 1.19B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.76 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.34 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.96 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences appoints new board member - Investing.com
Arcus Biosciences Appoints New Board Director - TipRanks
Arcus Biosciences Inc (RCUS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Stocks of Arcus Biosciences Inc (RCUS) are poised to climb above their peers - SETE News
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week LowWhat's Next? - MarketBeat
Arcus Biosciences' SWOT analysis: stock poised for growth amid clinical trials - MSN
Arcus Biosciences (NYSE:RCUS) Shares Up 4.1%Still a Buy? - MarketBeat
SG Americas Securities LLC Reduces Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (NYSE:RCUS) Hits New 12-Month LowShould You Sell? - MarketBeat
Arcus Biosciences stock hits 52-week low at $12.86 - MSN
Arcus Biosciences stock hits 52-week low at $12.86 By Investing.com - Investing.com Australia
Relative Strength Alert For Arcus Biosciences - Nasdaq
JPMorgan Chase & Co. Purchases 1,117 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
When the Price of (RCUS) Talks, People Listen - Stock Traders Daily
Arcus Biosciences Grants Stock Options and RSUs to New Key Employees - StockTitan
Arcus Biosciences (NYSE:RCUS) Stock Quotes, Forecast and News Summary - Benzinga
Arcus Biosciences (NYSE:RCUS) Stock Price Down 4.5%Here's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Reaches New 12-Month LowHere's What Happened - MarketBeat
Cantor Fitzgerald Forecasts RCUS FY2025 Earnings - Defense World
Arcus Biosciences stock hits 52-week low at $13.48 - MSN
Arcus Biosciences stock hits 52-week low at $13.48 By Investing.com - Investing.com Canada
Cantor Fitzgerald Weighs in on RCUS FY2025 Earnings - MarketBeat
Financial Survey: Barinthus Biotherapeutics (NASDAQ:BRNS) & Arcus Biosciences (NYSE:RCUS) - Defense World
Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer - BioSpace
Arcus Biosciences appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Arcus Biosciences appoints new Chief Medical Officer - Investing.com
Arcus Biosciences Announces New Chief Medical Officer - TipRanks
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Buy” by Analysts - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by Analysts - MarketBeat
Wells Fargo Initiates Coverage of Arcus Biosciences (RCUS) with Overweight Recommendation - MSN
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
How the (RCUS) price action is used to our Advantage - Stock Traders Daily
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025 - Seeking Alpha
Arcus Biosciences stock hits 52-week low at $13.51 By Investing.com - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Sets New 52-Week LowTime to Sell? - MarketBeat
Arcus: Excellent Pipeline And Collaborations, Cash Runway (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS investor three-year losses grow to 60% as the stock sheds US$79m this past week - Simply Wall St
Robert C. Goeltz II Sells 3,594 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) Stock - MarketBeat
Principal Financial Group Inc. Sells 18,777 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Geode Capital Management LLC Has $18.69 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays PLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Barclays PLC - MarketBeat
(RCUS) Trading Report - Stock Traders Daily
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Buy” by Brokerages - Defense World
Arcus Biosciences Grants Stock Options, RSUs to New Employees Under Inducement Plan - StockTitan
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):